You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 45 No. 2, February 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  NEUROLOGICAL REVIEW
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Amyotrophic Lateral Sclerosis

Recent Advances in Pathogenesis and Therapeutic Trials

Hiroshi Mitsumoto, MD; Maurice R. Hanson, MD; David A. Chad, MD, FRCP(C)

Arch Neurol. 1988;45(2):189-202.


Abstract

• We reviewed the current status of pathogenesis and therapeutic trials in amyotrophic lateral sclerosis (ALS). Clinical studies have identified several rare but definable causes for apparent ALS. Certain clinical features previously considered unlikely to occur in ALS are found on careful examination. Epidemiologic surveillance and recent studies of neurotoxic plant seeds used in Guam have shed light on the pathogenesis of endemic ALS. Extensive analyses of biochemical, metabolic, immunologic, viral, and toxic factors have provided provocative results requiring further studies. Reflecting on some of these hypotheses, therapeutic trials have been performed more vigorously than ever. Amyotrophic lateral sclerosis is now investigated at the molecular genetic level. Human autopsy and experimental animal studies have expanded our understanding of basic mechanisms involving motoneuronal degeneration. In the future, we must continue a relentless search for the pathogenesis of ALS, prospective clinical studies to define the limits of ALS, and well-designed, controlled therapeutic trials.



Author Affiliations

From the Department of Neurology, Cleveland Clinic Foundation (Drs Mitsumoto and Hanson), and the Department of Neurology, University of Massachusetts Medical School, Worcester (Dr Chad).


Footnotes

Accepted for publication Oct 6, 1987.

Reprint requests to Neuromuscular Program, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH 44106 (Dr Mitsumoto).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Clustering of Conjugal Amyotrophic Lateral Sclerosis in Southeastern France
Corcia et al.
Arch Neurol 2003;60:553-557.
ABSTRACT | FULL TEXT  

Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis
Desport et al.
Am. J. Clin. Nutr. 2001;74:328-334.
ABSTRACT | FULL TEXT  

Amyotrophic lateral sclerosis and hospice care
Enck
AM J HOSP PALLIAT CARE 1990;7:9-11.
 

Neurons in Onuf's Nucleus
Swift
Arch Neurol 1989;46:606-606.
ABSTRACT  

Amyotrophic Lateral Sclerosis
Brownell
Arch Neurol 1989;46:480-480.
ABSTRACT  

The Molecular Genetic Revolution: Its Impact on Clinical Neurology
Payne and Roses
Arch Neurol 1988;45:1366-1376.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.